The estimated Net Worth of Tamer I Khayal is at least $18 Milion dollars as of 3 September 2024. Tamer Khayal owns over 2,960 units of TransMedics stock worth over $3,423,109 and over the last 6 years he sold TMDX stock worth over $13,552,662. In addition, he makes $1,051,370 as Chief Commercial Officer at TransMedics.
Tamer has made over 39 trades of the TransMedics stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 2,960 units of TMDX stock worth $98,065 on 3 September 2024.
The largest trade he's ever made was selling 78,036 units of TransMedics stock on 1 May 2024 worth over $8,566,792. On average, Tamer trades about 8,986 units every 41 days since 2019. As of 3 September 2024 he still owns at least 23,803 units of TransMedics stock.
You can see the complete history of Tamer Khayal stock trades at the bottom of the page.
Dr. Tamer I. Khayal M.D. serves as Chief Commercial Officer of the Company. He served as our Chief Medical Officer and Vice President of Clinical Development from 2006 to 2017 and as our Director of Clinical Development from 2001 to 2006. Prior to joining TransMedics, Dr. Khayal served for six years as Director of Clinical Affairs for Zentiva Group, a.s., a pharmaceutical company, where he led clinical research, regulatory filings and clinical sales training for the company’s Middle East and Africa operations. Prior to his employment in the pharmaceutical industry, Dr. Khayal was a practicing physician.
As the Chief Commercial Officer of TransMedics, the total compensation of Tamer Khayal at TransMedics is $1,051,370. There are 1 executives at TransMedics getting paid more, with Waleed Hassanein having the highest compensation of $3,159,300.
Tamer Khayal is 51, he's been the Chief Commercial Officer of TransMedics since 2018. There are 14 older and 1 younger executives at TransMedics. The oldest executive at TransMedics Group, Inc. is James Tobin, 75, who is the Independent Chairman of the Board.
Tamer's mailing address filed with the SEC is C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, ANDOVER, MA, 01810.
Over the last 6 years, insiders at TransMedics have traded over $99,976,312 worth of TransMedics stock and bought 154,333 units worth $3,250,328 . The most active insiders traders include Edwin M Jr Kania, Waleed H Hassanein a James R Tobin. On average, TransMedics executives and independent directors trade stock every 10 days with the average trade being worth of $2,982,476. The most recent stock trade was executed by Tamer I Khayal on 3 September 2024, trading 2,960 units of TMDX stock currently worth $98,065.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
TransMedics executives and other stock owners filed with the SEC include: